drugset / Trial / NCT04268199

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

NCT04268199 ↗

Phase 2 Recruiting 100 enrolled AHS Cancer Control Alberta
NaSingle-groupOpen-labelTreatment

Summary

This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.

Timeline

Start
2020-05-29
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule — Subcutaneous

Indications